JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1995; 25:1111-1119
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heras, M
Right arrow Articles by Puga, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heras, M
Right arrow Articles by Puga, F.

High risk of thromboemboli early after bioprosthetic cardiac valve replacement

M Heras, JH Chesebro, V Fuster, WJ Penny, DE Grill, KR Bailey, GK Danielson, TA Orszulak, Pluth JR, FJ Puga, et al.

Division of Cardiovascular Disease, Mayo Clinic, Rochester, Minnesota.

OBJECTIVES. We studied the rate of thromboembolism in patients undergoing bioprosthetic replacement of the aortic or mitral valve, or both, at serial intervals after operation and the effects of anticoagulant or antiplatelet treatment and risk factors. BACKGROUND. Thromboembolism appears to occur early after operation, but the incidence, timing and risk factors for thromboembolism and the role, timing, adequacy, effectiveness, duration and risk of anticoagulation and antiplatelet agents are uncertain. METHODS. The rate of thromboembolism was studied at three time intervals after operation (1 to 10, 11 to 90 and > 90 days) in 816 patients who underwent bioprosthetic replacement of the aortic or mitral valve, or both, at the Mayo Clinic from January 1975 to December 1982. The effect of antithrombotic therapy (warfarin, aspirin or dipyridamole, alone or in combination) was evaluated. RESULTS. Median follow-up of surviving patients was 8.6 years. The rate of thromboembolism (%/year) decreased significantly (p < 0.01) at each time interval after operation (1 to 10, 11 to 90 and > 90 days) for mitral valve replacement (55%, 10% and 2.4%/year, respectively) and over the first time interval for aortic valve replacement (41%, 3.6% and 1.9%/year, respectively). During the first 10 days, 52% to 70% of prothrombin time ratios were low (< 1.5 x control). Patients with mitral valve replacement who received anticoagulation had a lower rate of thromboembolism for the entire follow-up period (2.5%/year with vs. 3.9%/year without anticoagulation, p = 0.05). Of 112 patients with a first thromboembolic episode, permanent disability occurred in 38% and death in 4%. Risk factors for emboli were lack of anticoagulation, mitral valve location, history of thromboembolism and increasing age. Only 10% of aortic, 44% of mitral and 17% of double valve recipients had anticoagulation at the time of an event. Patients with bleeding episodes (2.3%/year) were older and usually underwent anticoagulation. Blood transfusions were required in 60 of 111 patients (1.2%/year), and 13 patients (0.3%/year) died. CONCLUSIONS. Thromboembolic risk was especially high for aortic and mitral valve replacement for 90 days after operation, and overall was increased with lack of anticoagulation, mitral valve location, previous thromboembolism and increasing age. Anticoagulation reduced thromboemboli and appears to be indicated in all patients as early as possible for 3 months and thereafter in those with risk factors, but needs prospective testing.


This article has been cited by other articles:


Home page
CirculationHome page
2006 WRITING COMMITTEE MEMBERS, R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, et al.
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
Circulation, October 7, 2008; 118(15): e523 - e661.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al.
2008 Focused Update Incorporated Into the ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol., September 23, 2008; 52(13): e1 - e142.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit
Guideline on antiplatelet and anticoagulation management in cardiac surgery.
Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. L. Thompson, T. M. Sundt, M. E. Sarano, P. J. Santrach, and H. V. Schaff
In-patient international normalized ratio self-testing instruction after mechanical heart valve implantation.
Ann. Thorac. Surg., June 1, 2008; 85(6): 2046 - 2050.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. N. Salem, P. T. O'Gara, C. Madias, and S. G. Pauker
Valvular and Structural Heart Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest, June 1, 2008; 133(6_suppl): 593S - 629S.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. I. Aramendi and C.-A. Mestres
Antithrombotic therapy after bioprosthetic aortic valve replacement
Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 529 - 530.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
A. Colli, J.-P. Verhoye, R. Heijmen, J. T. Strauch, J. A.J. Hyde, D. Pagano, M. Antunes, H. Koertke, S. K. Ohri, D. H. L. Bail, et al.
Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results
Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 531 - 536.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Russo, F. Grigioni, J.-F. Avierinos, W. K. Freeman, R. Suri, H. Michelena, R. Brown, T. M. Sundt, and M. Enriquez-Sarano
Thromboembolic Complications After Surgical Correction of Mitral Regurgitation: Incidence, Predictors, and Clinical Implications
J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1203 - 1211.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
T. Gudbjartsson, T. Absi, and S. Aranki
Mitral Valve Replacement
Card. Surg. Adult, January 1, 2008; 3(2008): 1031 - 1068.
[Full Text]


Home page
Card Surg AdultHome page
H. V. Schaff and R. M. Suri
Multiple Valve Disease
Card. Surg. Adult, January 1, 2008; 3(2008): 1129 - 1158.
[Full Text]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Brueck, W. Kramer, P. Vogt, N. Steinert, P. Roth, G. Gorlach, M. Schonburg, and M. C. Heidt
Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors
Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 108 - 112.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
F. di Marco, S. Grendene, G. Feltrin, D. Meneghetti, and G. Gerosa
Antiplatelet therapy in patients receiving aortic bioprostheses: A report of clinical and instrumental safety
J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1597 - 1603.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
A. Colli, J.-P. Verhoye, A. Leguerrier, and T. Gherli
Anticoagulation or antiplatelet therapy of bioprosthetic heart valves recipients: an unresolved issue
Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 573 - 577.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Nowell, E. Wilton, H. Markus, and M. Jahangiri
Antithrombotic therapy following bioprosthetic aortic valve replacement
Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 578 - 585.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
W.R. E. Jamieson, S. D. Moffatt-Bruce, P. Skarsgard, M. A. Hadi, J. Ye, G. J. Fradet, J. G. Abel, M. T. Janusz, A. Cheung, and E. Germann
Early Antithrombotic Therapy for Aortic Valve Bioprostheses: Is There an Indication for Routine Use?
Ann. Thorac. Surg., February 1, 2007; 83(2): 549 - 557.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R. Roudaut, K. Serri, and S. Lafitte
Thrombosis of prosthetic heart valves: diagnosis and therapeutic considerations
Heart, January 1, 2007; 93(1): 137 - 142.
[Full Text] [PDF]


Home page
ICVTSHome page
M. El-Husseiny, K. Salhiyyah, S. G. Raja, and J. Dunning
Should warfarin be routinely prescribed for the first three months after a bioprosthetic valve replacement?
Interactive CardioVascular and Thoracic Surgery, October 1, 2006; 5(5): 616 - 623.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al.
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al.
ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons
J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
F. di Marco, M. Giordan, and G. Gerosa
Early antithrombotic therapy after aortic valve replacement with tissue valves: When the practice diverges from the guidelines
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1223 - 1223.
[Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
N. Zimmermann, T. Roussiekan, J. Winter, M. Kurt, E. Gams, F. Wenzel, and T. Hohlfeld
Platelet inhibition by aspirin after aortic valve replacement
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1392 - 1393.
[Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
A. Kulik, F. D. Rubens, P. S. Wells, C. Kearon, T. G. Mesana, J. van Berkom, and B.-K. Lam
Early Postoperative Anticoagulation After Mechanical Valve Replacement: A Systematic Review
Ann. Thorac. Surg., February 1, 2006; 81(2): 770 - 781.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. I. Aramendi, C.-A. Mestres, J. Martinez-Leon, V. Campos, G. Munoz, and C. Navas
Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial
Eur. J. Cardiothorac. Surg., May 1, 2005; 27(5): 854 - 860.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
T.M. Sundt, K.J. Zehr, J.A. Dearani, R.C. Daly, C.J. Mullany, C.G.A. McGregor, F.J. Puga, T.A. Orszulak, and H.V. Schaff
Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?
J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1024 - 1031.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
D. N. Salem, P. D. Stein, A. Al-Ahmad, H. I. Bussey, D. Horstkotte, N. Miller, and S. G. Pauker
Antithrombotic Therapy in Valvular Heart Disease--Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest, September 1, 2004; 126(3_suppl): 457S - 482S.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. Gherli, A. Colli, C. Fragnito, F. Nicolini, B. Borrello, S. Saccani, R. D'Amico, and C. Beghi
Comparing Warfarin With Aspirin After Biological Aortic Valve Replacement: A Prospective Study
Circulation, August 3, 2004; 110(5): 496 - 500.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
S. Schulman
Care of Patients Receiving Long-Term Anticoagulant Therapy
N. Engl. J. Med., August 14, 2003; 349(7): 675 - 683.
[Full Text] [PDF]


Home page
ICVTSHome page
J. I. Aramendi, C. A. Mestres, V. Campos, J. Martinez-Leon, C. Pontes, G. Munoz, and J. C. Navas
Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (TRAC): rationale and design for a prospective, randomized, co-operative trial
Interactive CardioVascular and Thoracic Surgery, June 1, 2003; 2(2): 170 - 174.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
N. D. Desai and G. T. Christakis
Stented Mechanical/Bioprosthetic Aortic Valve Replacement
Card. Surg. Adult, January 1, 2003; 2(2003): 825 - 856.
[Full Text]


Home page
Card Surg AdultHome page
T. Gudbjartsson, S. Aranki, and L. H. Cohn
Mechanical/Bioprosthetic Mitral Valve Replacement
Card. Surg. Adult, January 1, 2003; 2(2003): 951 - 986.
[Full Text]


Home page
Card Surg AdultHome page
H. V. Schaff and D. H. Marsh
Multiple Valve Disease
Card. Surg. Adult, January 1, 2003; 2(2003): 1017 - 1045.
[Full Text]


Home page
Eur Heart J SupplHome page
K. Schror
Combination of oral anticoagulant and platelet inhibitor drugs: focus on the pharmacological aspects of optimizing antithrombotic therapy in mechanical heart valve replacement
Eur. Heart J. Suppl., December 1, 2001; 3(suppl_Q): Q54 - Q59.
[Abstract] [PDF]


Home page
ChestHome page
P. D. Stein, J. S. Alpert, H. I. Bussey, J. E. Dalen, and A. G.G. Turpie
Antithrombotic Therapy in Patients With Mechanical and Biological Prosthetic Heart Valves
Chest, January 1, 2001; 119(1_suppl): 220S - 227S.
[Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
W. E. Jamieson, E. Germann, G. J Fradet, S. V Lichtenstein, R. T Miyagishima, W. E. Jamieson, E. Germann, G. J Fradet, S. V Lichtenstein, and R. T Miyagishima
Bioprostheses and Mechanical Prostheses Predictors of Performance
Asian Cardiovasc Thorac Ann, June 1, 2000; 8(2): 121 - 126.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E. Weinschelbaum, P. Stutzbach, M. Oliva, J. Zaidman, A. Torino, and E. Gabe
MANUAL DEBRIDEMENT OF THE AORTIC VALVE IN ELDERLY PATIENTS WITH DEGENERATIVE AORTIC STENOSIS
J. Thorac. Cardiovasc. Surg., June 1, 1999; 117(6): 1157 - 1165.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. H. Chesebro and V. Fuster
Optimal Antithrombotic Therapy for Mechanical Prosthetic Heart Valves
Circulation, November 1, 1996; 94(9): 2055 - 2056.
[Full Text]


Home page
NEJMHome page
W. Vongpatanasin, L. D. Hillis, and R. A. Lange
Prosthetic Heart Valves
N. Engl. J. Med., August 8, 1996; 335(6): 407 - 416.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1995 by the American College of Cardiology Foundation.